Squibb Diagnostics' Cardio Tec (Tc 99m teboroxime)
Executive Summary
Radioactive forms of the myocardial perfusion agent will be distributed exclusively by radiopharmacies operator Syncor. Under the agreement, Squibb will sell non-radioactive forms of Cardio Tec to medical centers that perform their own radioactive compounding. Cardiotec was recommended for approval Nov. 17 by the FDA Radiopharmaceutical Committee for use in distinguishing normal from abnormal myocardium in patients with suspected coronary artery disease.
You may also be interested in...
Sandoz And Samsung Celebrate Stelara Rival’s EU Approval
Sandoz and Samsung Bioepis have received final European Commission approval for their partnered Pyzchiva biosimilar rival to Stelara. But with European competition on ustekinumab due to kick off in just a matter of months, further applicants are also waiting in the wings.
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.